Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics, Inc. (HOWL) agreed to merge Ambros Therapeutics, Inc. into a wholly owned subsidiary, with the deal structured as a tax-free reorganization. Ambros stockholders will receive Werewolf common stock based on an exchange ratio, with the option to receive Merger Pre-Funded Warrants above a Beneficial Ownership Limitation.
Based on pro forma assumptions, legacy Werewolf equityholders (excluding PIPE participants) are expected to own 6.8% of the combined company, Ambros stockholders 71.7%, and PIPE investors 21.5%, reflecting implied valuations of $47.5 million for Werewolf and $500.0 million for Ambros. Concurrently, Werewolf entered into a $150.0 million private placement of common stock and PIPE pre-funded warrants, which must deliver at least $100.0 million in net cash proceeds at closing.
Werewolf will also issue one non-transferable contingent value right (CVR) per outstanding Werewolf share, entitling holders to potential cash payments tied to monetization of legacy INDUKINE programs WTX-124 and WTX-330, with no assurance of any payment. The merger requires stockholder approvals, Nasdaq listing and registration effectiveness, and that Werewolf Net Cash be greater than zero; customary termination fees of $20.0 million (Ambros) and $1.9 million (Werewolf) may apply in specified deal-failure scenarios.
Werewolf Therapeutics, Inc. (HOWL) entered into a definitive all‑stock merger agreement to combine with Ambros Therapeutics, with Ambros becoming a wholly owned subsidiary and the combined company expected to operate as Ambros Therapeutics and trade on Nasdaq as “AMBX.” Ambros stockholders will receive Werewolf common stock or pre‑funded warrants based on an exchange ratio reflecting an implied $500.0 million valuation for Ambros and $47.5 million for Werewolf.
On a fully diluted, treasury‑stock basis, pre‑merger Werewolf holders (excluding PIPE participants) are expected to own 6.8% of the combined company, pre‑merger Ambros stockholders 71.7%, and PIPE investors 21.5%, subject to adjustments including Werewolf net cash. Concurrently, Werewolf agreed to a $150.0 million private placement of common stock and PIPE pre‑funded warrants, with proceeds expected to fund Ambros’s pivotal CRPS‑RISE Phase 3 trial of neridronate and a planned NDA submission, providing cash runway into the first half of 2029. Existing Werewolf holders will receive one non‑transferable contingent value right per share tied to potential monetization of Werewolf’s legacy INDUKINE assets.
Werewolf Therapeutics, Inc. (HOWL) entered into an asset purchase agreement with EMD Serono Research & Development Institute Inc. on August 14, 2026, selling pre-clinical technology comprising its INDUCER platform and its INDUKINE platform (excluding the WTX-124 and WTX-330 clinical development programs) as the Transferred Assets. Werewolf retains all rights needed to continue developing its WTX-124 and WTX-330 clinical programs.
As consideration, EMD agreed to pay Werewolf upfront cash of $28.0 million plus an additional $5.0 million upon completion of the technology transfer. The parties provided customary representations, warranties, indemnities and a non-competition covenant under which Werewolf will not exploit certain compounds directed to the same tumor targets as any Transferred Compound for 24 months after closing, subject to change-of-control exceptions. Concurrently, EMD granted Werewolf an exclusive license to certain Transferred Assets patents necessary to conduct clinical development for WTX-124 and WTX-330, and additional license rights to support Werewolf’s existing collaboration arrangements with Harpoon Therapeutics, Inc. and Jazz Pharmaceuticals Ireland Limited.
Werewolf Therapeutics reported $21.0 million collaboration revenue in the second quarter of 2026 from selling its IFNα 898 Program to Jazz Pharmaceuticals, producing quarterly net income of $3.7 million after a prior-year loss. For the first half of 2026, the company still recorded a net loss of $9.9 million as R&D fell to $14.3 million and G&A rose to $12.8 million, reflecting a sharp pullback in development spending and higher advisory and legal costs tied to a strategic review.
Werewolf ended June 30, 2026 with $22.0 million in cash and cash equivalents and has fully repaid its $30.0 million K2 HealthVentures term loan via a $31.4 million payment, eliminating secured debt but triggering a $3.4 million extinguishment loss. Management discloses “substantial doubt” about the ability to continue as a going concern for at least twelve months and is exploring strategic alternatives, including a sale or partnerships, while executing a 2026 restructuring with major workforce reductions and an expected $6.5 million in total restructuring costs. Lead oncology programs WTX-124 and WTX-330 remain in early-stage trials targeted to complete in the fourth quarter of 2026, but further development will require additional funding or partners.
Werewolf Therapeutics, Inc. reported second quarter 2026 results highlighted by a shift to profitability and a major asset transaction. The company entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited for its JZP898 program and repaid all amounts owed under its loan and security agreement with K2 HealthVentures LLC. These transactions included a $21.0 million payment to Werewolf and support ongoing evaluation of strategic alternatives with financial advisor Piper Sandler.
For the quarter ended June 30, 2026, collaboration revenue was $21.0 million, research and development expenses were $6.2 million versus $13.1 million a year earlier, and general and administrative expenses were $7.7 million versus $4.4 million. Net income was $3.7 million, compared with a net loss of $18.0 million in the prior-year period. As of June 30, 2026, cash and cash equivalents were $22.0 million, compared with $46.5 million as of March 31, 2026, and management expects existing cash to fund operations into the second quarter of 2027 while advancing INDUKINE and INDUCER pipeline programs, including WTX-124 and WTX-330.
Werewolf Therapeutics director Luke Evnin reported indirect open-market sales of 143,199 shares of Common Stock over two days. On July 6, 2026, entities associated with him sold 35,770 shares at a weighted average price of $0.32 per share. On July 7, 2026, they sold a further 107,429 shares at a weighted average price of $0.31 per share.
The trades were executed by multiple MPM-affiliated investment entities and carried out under a pre-established Rule 10b5-1 trading plan dated March 26, 2026. Following these transactions, those entities reported holding no shares of Werewolf Therapeutics.